CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023GlobeNewsWire • 11/02/23
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/26/23
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of NephrologyGlobeNewsWire • 09/08/23
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product DefencathGlobeNewsWire • 08/30/23
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/23
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/29/23
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/28/23
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCathGlobeNewsWire • 06/21/23
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream InfectionsGlobeNewsWire • 06/15/23
CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023GlobeNewsWire • 05/08/23
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCathGlobeNewsWire • 05/01/23
Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of DirectorsGlobeNewsWire • 04/17/23
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%Zacks Investment Research • 04/12/23